{"id":328215,"date":"2026-10-27T12:20:50","date_gmt":"2026-10-27T06:50:50","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=328215"},"modified":"2026-10-27T12:20:50","modified_gmt":"2026-10-27T06:50:50","slug":"specialty-branded-generics-seller-respiratory-and-anti-infective-leader-and-research-driven-pharma-company-stocks-roadmap-vertex-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/specialty-branded-generics-seller-respiratory-and-anti-infective-leader-and-research-driven-pharma-company-stocks-roadmap-vertex-list\/","title":{"rendered":"3 Specialty Branded Generics Seller, Respiratory and Anti-Infective Leader and Research-Driven Pharma Company Stocks With a Strong Future Roadmap: Ajanta Pharma, Cipla and Glenmark Pharmaceuticals"},"content":{"rendered":"

Ajanta Pharma, Cipla and Glenmark Pharmaceuticals: ROE of 11.3% to 28.1% and FY22 to FY26 revenue CAGR of 7.1% to 12.9%. Prices as of 26 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The three eye care, respiratory and research pharma stocks to watch are Ajanta Pharma, Cipla and Glenmark Pharmaceuticals. Their return on equity ranges from 11.3% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 12.9%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Ajanta Pharma has the fastest revenue growth at 12.9% a year. Prices are based on the 26 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n

Eye care, respiratory and research pharma stocks let investors follow companies that serve a growing part of the Indian economy. Ajanta Pharma, Cipla and Glenmark Pharmaceuticals cover a specialty branded generics seller, a respiratory and anti-infective leader and a research-driven pharma company.<\/p>\n

This list covers three eye care, respiratory and research pharma stocks with complete current figures: Ajanta Pharma, Cipla and Glenmark Pharmaceuticals. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n